Dr Saad Al-Ismail told the Inquiry that "maybe in retrospect it was probably a misplaced trust in the medicine licensing agency in the UK, in that we never used a product which is not licensed. We never used a product which has not proved to be efficacious." Read more about Dr Saad Al-Ismail told the Inquiry that "maybe in retrospect it was probably a misplaced trust in the medicine licensing agency in the UK, in that we never used a product which is not licensed. We never used a product which has not proved to be efficacious."
It was stated regarding a Hepatitis Survey that all the cases of clinical hepatitis and almost all asymptomatic hepatitis were confined to patients restricted to commercial concentrates. No significant differences between Hemofil and Kryobulin. Read more about It was stated regarding a Hepatitis Survey that all the cases of clinical hepatitis and almost all asymptomatic hepatitis were confined to patients restricted to commercial concentrates. No significant differences between Hemofil and Kryobulin.
In her written statement to the Infected Blood Inquiry, Dr Diana Walford elaborated on the translation of a German note regarding a "publication" showing that American Kryobulin had a higher hepatitis risk. Read more about In her written statement to the Infected Blood Inquiry, Dr Diana Walford elaborated on the translation of a German note regarding a "publication" showing that American Kryobulin had a higher hepatitis risk.
In her written witness statement to the Infected Blood Inquiry, Dr Diana Waford made reference to the Immuno's ethical obligation regarding American Kryobulin carrying a higher risk of hepatitis. Read more about In her written witness statement to the Infected Blood Inquiry, Dr Diana Waford made reference to the Immuno's ethical obligation regarding American Kryobulin carrying a higher risk of hepatitis.
In a memo from Mr Wrigglesworth to Mr Parker and others it was recorded that "Miles Labs state that FVIII manufactured from plasma collected since March 83' will not be available until August, and Immuno in September 83'". Read more about In a memo from Mr Wrigglesworth to Mr Parker and others it was recorded that "Miles Labs state that FVIII manufactured from plasma collected since March 83' will not be available until August, and Immuno in September 83'".
A table published in June 1983 showed that Immuno Ltd's sales of Kryobulin (Red) exceeded sales of Kryobulin (Blue) by 4.5 times. Read more about A table published in June 1983 showed that Immuno Ltd's sales of Kryobulin (Red) exceeded sales of Kryobulin (Blue) by 4.5 times.
In an internal memo, Dr Otto Schwarz managing director of Immuno AG stated that two types of Kryobulin would be sold. KRYOBULIN 1, made from European plasma and KRYOBULIN 2, made from US Licensed Source Plasma. Read more about In an internal memo, Dr Otto Schwarz managing director of Immuno AG stated that two types of Kryobulin would be sold. KRYOBULIN 1, made from European plasma and KRYOBULIN 2, made from US Licensed Source Plasma.
When marketing Factor 8 Concentrates produced from plasma of US origin and the European based material one, no distinction was made between the labelling nor the accompanying information sheets in order for clinicians to pick whichever they wanted to use. Read more about When marketing Factor 8 Concentrates produced from plasma of US origin and the European based material one, no distinction was made between the labelling nor the accompanying information sheets in order for clinicians to pick whichever they wanted to use.
It was mentioned at the Haemophilia Reference Centre Directors meeting that the European (red) material was still available for those who felt it carried a lower risk of conveying hepatitis, although both were equally safe. Read more about It was mentioned at the Haemophilia Reference Centre Directors meeting that the European (red) material was still available for those who felt it carried a lower risk of conveying hepatitis, although both were equally safe.
At the Haemophilia Reference Centre Directors meeting it was suggested the implication was that the cheaper (Kryobulin produced in the US) product carried the higher risk of plasma viral hepatitis which worried some Directors. Read more about At the Haemophilia Reference Centre Directors meeting it was suggested the implication was that the cheaper (Kryobulin produced in the US) product carried the higher risk of plasma viral hepatitis which worried some Directors.